Literature DB >> 15956542

Compartmentalized human immunodeficiency virus type 1 present in cerebrospinal fluid is produced by short-lived cells.

Patrick R Harrington1, David W Haas, Kimberly Ritola, Ronald Swanstrom.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) invades the central nervous system (CNS) during primary infection and persists in this compartment by unknown mechanisms over the course of infection. In this study, we examined viral population dynamics in four asymptomatic subjects commencing antiretroviral therapy to characterize cellular sources of HIV-1 in the CNS. The inability to monitor viruses directly in the brain poses a major challenge in studying HIV-1 dynamics in the CNS. Studies of HIV-1 in cerebrospinal fluid (CSF) provide a useful surrogate for the sampling of virus in the CNS, but they are complicated by the fact that infected cells in local CNS tissues and in the periphery contribute to the population pool of HIV-1 in CSF. We utilized heteroduplex tracking assays to differentiate CSF HIV-1 variants that were shared with peripheral blood plasma from those that were compartmentalized in CSF and therefore presumably derived from local CNS tissues. We then tracked the relative decline of individual viral variants during the initial days of antiretroviral therapy. We found that HIV-1 variants compartmentalized in CSF declined rapidly during therapy, with maximum half-lives of approximately 1 to 3 days. These kinetics emulate the decline in HIV-1 produced from short-lived CD4+ T cells in the periphery, suggesting that a similarly short-lived, HIV-infected cell population exists within the CNS. We propose that short-lived CD4+ T cells trafficking between the CNS and the periphery play an important role in amplifying and maintaining HIV-1 populations in the CNS during the asymptomatic phase of infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15956542      PMCID: PMC1143772          DOI: 10.1128/JVI.79.13.7959-7966.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

1.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.

Authors:  Janet D Siliciano; Joleen Kajdas; Diana Finzi; Thomas C Quinn; Karen Chadwick; Joseph B Margolick; Colin Kovacs; Stephen J Gange; Robert F Siliciano
Journal:  Nat Med       Date:  2003-05-18       Impact factor: 53.440

Review 2.  Three or more routes for leukocyte migration into the central nervous system.

Authors:  Richard M Ransohoff; Pia Kivisäkk; Grahame Kidd
Journal:  Nat Rev Immunol       Date:  2003-07       Impact factor: 53.106

Review 3.  HIV-1 dynamics in vivo: implications for therapy.

Authors:  Viviana Simon; David D Ho
Journal:  Nat Rev Microbiol       Date:  2003-12       Impact factor: 60.633

Review 4.  Pathogenesis of human immunodeficiency virus-induced neurological disease.

Authors:  Andrew V Albright; Samantha S Soldan; Francisco González-Scarano
Journal:  J Neurovirol       Date:  2003-04       Impact factor: 2.643

5.  HIV-producing T cells in cerebrospinal fluid.

Authors:  Jutta K Neuenburg; Elizabeth Sinclair; Annelie Nilsson; Christophe Kreis; Peter Bacchetti; Richard W Price; Robert M Grant
Journal:  J Acquir Immune Defic Syndr       Date:  2004-10-01       Impact factor: 3.731

6.  Multiple V1/V2 env variants are frequently present during primary infection with human immunodeficiency virus type 1.

Authors:  Kimberly Ritola; Christopher D Pilcher; Susan A Fiscus; Noah G Hoffman; Julie A E Nelson; Kathryn M Kitrinos; Charles B Hicks; Joseph J Eron; Ronald Swanstrom
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

7.  Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration.

Authors:  Christian Eggers; Kurt Hertogs; Hans-Jörg Stürenburg; Jan van Lunzen; Hans-Jürgen Stellbrink
Journal:  AIDS       Date:  2003-09-05       Impact factor: 4.177

8.  Two phases of HIV RNA decay in CSF during initial days of multidrug therapy.

Authors:  D W Haas; B W Johnson; P Spearman; S Raffanti; J Nicotera; D Schmidt; T Hulgan; R Shepard; S A Fiscus
Journal:  Neurology       Date:  2003-11-25       Impact factor: 9.910

9.  Turnover of env variable region 1 and 2 genotypes in subjects with late-stage human immunodeficiency virus type 1 infection.

Authors:  Kathryn M Kitrinos; Noah G Hoffman; Julie A E Nelson; Ronald Swanstrom
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

10.  Increased adhesion molecule and chemokine receptor expression on CD8+ T cells trafficking to cerebrospinal fluid in HIV-1 infection.

Authors:  Barbara L Shacklett; Catherine A Cox; David T Wilkens; R Karl Karlsson; Annelie Nilsson; Douglas F Nixon; Richard W Price
Journal:  J Infect Dis       Date:  2004-05-24       Impact factor: 5.226

View more
  31 in total

1.  Independent evolution of human immunodeficiency virus type 1 env V1/V2 and V4/V5 hypervariable regions during chronic infection.

Authors:  Patrick R Harrington; Julie A E Nelson; Kathryn M Kitrinos; Ronald Swanstrom
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

2.  Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin.

Authors:  Richard W Price; Robin Parham; Jing Lu Kroll; Stephen A Wring; Brian Baker; Jeff Sailstad; Rebecca Hoh; Teri Liegler; Serena Spudich; Daniel R Kuritzkes; Steven G Deeks
Journal:  Antivir Ther       Date:  2008

3.  HIV variability in the liver and evidence of possible compartmentalization.

Authors:  Jason T Blackard; Gang Ma; Christina M Martin; Susan D Rouster; M Tarek Shata; Kenneth E Sherman
Journal:  AIDS Res Hum Retroviruses       Date:  2011-05-04       Impact factor: 2.205

Review 4.  HIV/neuroAIDS biomarkers.

Authors:  Pejman Rahimian; Johnny J He
Journal:  Prog Neurobiol       Date:  2016-04-12       Impact factor: 11.685

5.  Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection.

Authors:  Gretja Schnell; Richard W Price; Ronald Swanstrom; Serena Spudich
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

Review 6.  NeuroAIDS: characteristics and diagnosis of the neurological complications of AIDS.

Authors:  Alireza Minagar; Deborah Commins; J Steven Alexander; Romy Hoque; Francesco Chiappelli; Elyse J Singer; Behrooz Nikbin; Paul Shapshak
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

7.  Major coexisting human immunodeficiency virus type 1 env gene subpopulations in the peripheral blood are produced by cells with similar turnover rates and show little evidence of genetic compartmentalization.

Authors:  William L Ince; Patrick R Harrington; Gretja L Schnell; Milloni Patel-Chhabra; Christina L Burch; Prema Menezes; Richard W Price; Joseph J Eron; Ronald I Swanstrom
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

8.  Failure of atorvastatin to modulate CSF HIV-1 infection: results of a pilot study.

Authors:  J C Probasco; S S Spudich; J Critchfield; E Lee; N Lollo; S G Deeks; R W Price
Journal:  Neurology       Date:  2008-08-12       Impact factor: 9.910

9.  Envelope gene evolution and HIV-1 neuropathogenesis.

Authors:  Fabián J Vázquez-Santiago; Vanessa Rivera-Amill
Journal:  J Neuroinfect Dis       Date:  2015-08-20

10.  Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy.

Authors:  Aylin Yilmaz; Richard W Price; Serena Spudich; Dietmar Fuchs; Lars Hagberg; Magnus Gisslén
Journal:  J Acquir Immune Defic Syndr       Date:  2008-02-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.